Target (CBDY) Other Non-Current Liabilities (2019 - 2026)
Target (CBDY) reported Other Non-Current Liabilities of $10.4 million for Q1 2026, up 31612124.24% year-over-year from N/an in Q1 2025, and up 0.68% quarter-over-quarter from $10.4 million in Q4 2025.
Target (CBDY) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
Target (CBDY) has 8 years of Other Non-Current Liabilities data on file, last reported at $10.4 million in Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $10.4 million, up 31612124.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.4 million (up 31612124.24% YoY), and the FY2025 annual result was $10.4 million, up 24670319.05% from the prior year.
- Other Non-Current Liabilities climbed to $10.4 million in Q1 2026 per CBDY's latest filing, from $10.4 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $10.4 million in Q1 2026 and troughed at $7.0 in Q2 2025.
- A 5-year average of $1.8 million and a median of $647.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2026: Other Non-Current Liabilities sank 99.98% in 2022, then surged 31612124.24% in 2026.
- A 5-year view of Other Non-Current Liabilities shows it stood at $489.0 in 2022, then retreated by 27.4% to $355.0 in 2023, then plunged by 88.17% to $42.0 in 2024, then soared by 24670319.05% to $10.4 million in 2025, then rose by 0.68% to $10.4 million in 2026.
- Business Quant data shows CBDY's Other Non-Current Liabilities at $10.4 million in Q1 2026, $10.4 million in Q4 2025, and $10.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Target | - | - | 191,787.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.43 Mn |
| Dec 31, 2025 | 10.36 Mn |
| Sep 30, 2025 | 10.20 Mn |
| Jun 30, 2025 | 7.00 |
| Mar 31, 2025 | 33.00 |
| Dec 31, 2024 | 42.00 |
| Sep 30, 2024 | 414.00 |
| Jun 30, 2024 | 647.00 |
| Mar 31, 2024 | 696.00 |
| Dec 31, 2023 | 355.00 |
| Sep 30, 2023 | 1,770.00 |
| Jun 30, 2023 | 931.00 |
| Mar 31, 2023 | 345.00 |
| Dec 31, 2022 | 489.00 |
| Sep 30, 2022 | 468.00 |
| Jun 30, 2022 | 764.00 |
| Mar 31, 2022 | 1,080.00 |
| Dec 31, 2021 | 22,095.00 |
| Sep 30, 2021 | 744,802.00 |
| Jun 30, 2021 | 3.59 Mn |